A continuing medical education and nursing continuing professional development activity provided by NAMCP and AAMCN.
This activity is an archive from the live session from the 2025 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.
This activity is valid from June 1, 2025 to August 1, 2026
Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the evaluation and post test. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete it. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the "download" button after completing the post test.
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
This activity is supported by an educational grant from
Regeneron Pharmaceuticals
Description:
Retinal diseases are those that affect the retina, or the back layer of your eye. A retinal disease can affect any part of the retina, including the macula. Many retinal diseases cause symptoms that affect a patient's vision. It's important to find and treat diseases of the retina, as many of them can cause blindness or low vision if they aren't treated. Retinal diseases including age-related macular degeneration (AMD) and diabetic retinopathy/diabetic macular edema (DR/DME) pose a significant burden to patients and the health care system. Fortunately for patients with AMD and DR/DME, intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of retinal disease and improved patient outcomes, especially in the area of dosing intervals which have improved quality of life for patients with less frequent injections. However, while the clinical benefits of these compounds are well documented their use brings up other issues for ophthalmologists, namely, cost. In addition to time requirements for appointments for intravitreal injections of anti-VEGF inhibitors and post-injection recovery, the cost of anti-VEGF therapies may limit patient access as well. Managed care professionals, including physician medical directors, must ensure that retinal specialists and patients have access to a variety of anti-VEGF therapies so that treatment can be individualized. Managed care medical directors, pharmacists and nurse case managers need education on the differentiating factors of available anti-VEGF therapies for AMD and DR/DME and emerging agents to equip clinicians to ensure appropriate communication occurs with retinal specialists so that patients receive timely, effective, and comprehensive treatment.
Upon completion of this activity, participants will be able to:
Faculty:
Priya Vakharia, MD
Retina Vitreous Associates of Florida
pvakharia@rvaf.com
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Vakharia has served as a consultant for AbbVie, Aliph, ANI Pharmaceuticals, Annexon, Apellis, Bausch and Lomb, Bayer, Coherus, EyePoint, Genentech, Heidelberg, Notal Vision, Novartis, Ocuphire, Regeneron. He has received grant/research support from 4DMT, Alcon, Alexion, Allgenesis, Annexon, Astellas, Aviceda, Bayer, Eyebiotech, Genentech, Ionis, Kirwin, Kodiak, Kyoto, Kyowo Kirin, Notal Vision, Novartis, Ocular Therapeutics, Ocuterra, ONL Therapeutics, Opthea, Pfizer, Priovant Therapeutics, Recens Medical, Regeneron, RegenxBio, Stealth Biotherapeutics, and Unity. She has served as a speaker for Astellas, Bausch and Lomb, Genentech, and Regeneron. All relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.
The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.
This activity is supported by an educational grant from
Regeneron Pharmaceuticals
NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.